Search results
Results From The WOW.Com Content Network
When the cells are collected from the same patient on whom they will be used, a graft is called autologous. Syngeneic refers to a graft transferred between genetically identical animals or people. [1] A syngeneic graft is known as an isograft. [2] Related terms include: [citation needed]
A more recent clinical trial showed that allogeneic fetal MSCs transplanted in utero in patients with severe OI can engraft and differentiate into bone in a human fetus. [42] Besides bone and cartilage regeneration, cardiomyocyte regeneration with autologous BM MSCs has also been reported recently.
Haematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent haematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. [10] [11] [12] It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical ...
A common example is the removal of a piece of bone (usually from the hip) and its being ground into a paste for the reconstruction of another portion of bone. Autotransplantation, although most common with blood, bone, hematopoietic stem cells, or skin, can be used for a wide variety of organs. One of the rare examples is autotransplantation of ...
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood, in order to replicate inside a patient and produce additional normal blood cells.
Autologous chondrocyte implantation (ACI, ATC code M09AX02 ) is a biomedical treatment that repairs damages in articular cartilage. ACI provides pain relief while at the same time slowing down the progression or considerably delaying partial or total joint replacement ( knee replacement ) surgery.
Autologous matrix-induced chondrogenesis (AMIC) is a treatment for articular cartilage damage. It combines microfracture surgery with the application of a bi-layer collagen I/III membrane. There is tentative short to medium term benefits as of 2017.
The use of autologous cells in microencapsulation therapy is limited by the availability of these cells and even though xenogeneic cells are easily accessible, danger of possible transmission of viruses, especially porcine endogenous retrovirus to the patient restricts their clinical application, [67] and after much debate several groups have ...